Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cardinal Health Inc (CAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cardinal Health Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Cardinal Health Inc trades at $236.48 (market cap $55.23B). The key difference: Cardinal Health Inc is far larger — about 66.9× Amphastar Pharmaceuticals Inc's market cap, and Cardinal Health Inc pays a 0.87% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CAH | |
|---|---|---|
Market Cap | $826.08M | $55.23B |
Sector | Health | Health |
52-Week High | $30.81 | $239.71 |
52-Week Low | $16.87 | $146.04 |
Enterprise Value | $1.22B | $60.20B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Cardinal Health (CAH) trades at $235.80, up 0.87% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 37.08% ROE and positive revenue growth trends from $222.58B in 2025 to projected $250.7B in 2026. Recent removal from Russell indices has not dampened analyst optimism, with 54.55% maintaining buy ratings and a $248 consensus price target representing 5% upside potential.
The outlook remains positive given CAH's defensive healthcare distribution business and specialty pharma expansion. Key risks include negative shareholder equity of -$3.21B and elevated debt levels with 16.09% debt-to-asset ratio. Earnings momentum from three consecutive quarterly beats supports the bullish case, though investors should monitor the upcoming Q2 2026 results against $2.41 EPS expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
